Core Insights - Profusa, Inc. has launched its Healthcare Research version of the Lumee tissue oxygen monitoring system targeting the global CRO market, which is projected to reach $47.9 billion by 2025, growing at a CAGR of 7% [1][3] - The initiative aims to meet the increasing demand for real-time biological data in drug development, allowing CRO partners to integrate the technology into their workflows with minimal implementation risk [2][4] Company Developments - Profusa's Lumee tissue oxygen products are commercially available and ready for immediate deployment, providing continuous, real-time measurement of tissue oxygenation for various research applications [4] - The company has appointed Sean Givens as the Head of Government and Healthcare Research Business to lead commercialization efforts, emphasizing the strong interest in their validated sensors across the industry [5][6] Market Context - The CRO and pharmaceutical services market is experiencing robust growth due to rising R&D investments and regulatory support for new methodologies, with forecasts indicating the market could expand to over $91.2 billion by 2034 [3] - Profusa's technology supports research in critical areas such as wound healing and oncology, where understanding tissue oxygen dynamics is essential for therapeutic responses [4]

Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the launch of its Healthcare Researc ...

Core Insights - Profusa, Inc. is expanding its customer base in Europe through a collaboration with AZ Sint Blasius Hospital in Belgium, led by Dr. Koen Deloose, a recognized expert in critical limb ischemia [1][3] - Dr. Deloose's clinic employs a multidisciplinary approach to treat patients, integrating specialists in diabetic foot care, wound care, and podiatry [2] - Profusa's Lumee Oxygen monitoring system is expected to enhance treatment outcomes for patients with critical limb ischemia by providing real-time tissue oxygen metrics [2][3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemical data [4] - The company aims to provide affordable, long-lasting biosensors that deliver actionable medical-grade data for both personal and clinical use [4] Leadership and Research - Dr. Koen Deloose has a significant background in vascular medicine, having authored over 200 articles in peer-reviewed journals and holding leadership roles in various medical organizations [2] - Profusa's CEO, Ben Hwang, emphasizes the alignment of Dr. Deloose's clinical work with the company's mission to improve health through accessible biochemical monitoring [3]

Core Insights - Profusa, Inc. has announced a collaboration with Prof. Dr. Marianne Brodmann from the Medical University of Graz, Austria, to adopt the Lumee oxygen platform technology in her practice, which involves approximately 1,500 annual vascular procedures [1][2] - Prof. Brodmann, as the principal investigator of clinical studies that supported Lumee oxygen's CE marking, will integrate Profusa's platform technology into clinical study programs [1][2] - The collaboration aims to validate the Lumee technology platform and expand its market reach through integration into clinical practices [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical-grade data [4] - The company aims to offer long-lasting, injectable, and affordable biosensors, creating a personalized biochemical signature for reliable clinical use [4]

Core Insights - Profusa, Inc. has announced significant leadership changes, including the appointment of Peter O'Rourke as lead independent director and Fred Knechtel as Chief Financial Officer, following its business combination with NorthView Acquisition Corp [1][2] - The company is positioned at a critical juncture as it prepares to launch its innovative biosensor platform into global markets, with leadership bringing extensive experience in healthcare and finance [2][3] Leadership Appointments - Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, brings a wealth of experience overseeing a large healthcare system serving over 9 million veterans across 1,300 facilities [2][3] - Fred Knechtel has a strong background in finance and operations, having worked with various companies in sectors such as life sciences and automotive, and has been a trusted partner to Profusa [2][3][4] Company Vision and Technology - Profusa aims to revolutionize health monitoring through its biosensor technology, which is designed to provide continuous, actionable medical-grade data [4] - The company focuses on developing long-lasting, injectable biosensors that offer personalized biochemical signatures for both personal and medical use [4]